Sorafenib relieves cell‐intrinsic and cell‐extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
ML Chen, BS Yan, WC Lu, MH Chen… - … journal of cancer, 2014 - Wiley Online Library
Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
ML Chen, BS Yan, WC Lu, MH Chen… - … journal of cancer, 2014 - pubmed.ncbi.nlm.nih.gov
Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
ML Chen, BS Yan, WC Lu, MH Chen, SL Yu… - … Journal of Cancer, 2013 - europepmc.org
Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
[引用][C] Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
ML CHEN, BS YAN, WC LU, MH CHEN… - … journal of cancer …, 2014 - pascal-francis.inist.fr
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor
microenvironment to augment antitumor immunity CNRS Inist Pascal-Francis CNRS Pascal …
microenvironment to augment antitumor immunity CNRS Inist Pascal-Francis CNRS Pascal …
Sorafenib relieves cell‐intrinsic and cell‐extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
ML Chen, BS Yan, WC Lu, MH Chen, SL Yu… - International Journal of …, 2013 - infona.pl
Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
ML Chen, BS Yan, WC Lu, MH Chen… - … Journal of Cancer, 2014 - search.ebscohost.com
Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
Sorafenib relieves cell‐intrinsic and cell‐extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
ML Chen, BS Yan, WC Lu, MH Chen, SL Yu… - International Journal of …, 2013 - cir.nii.ac.jp
抄録< jats: p> Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the
standard of care for patients with advanced hepatocellular carcinoma (HCC). Cumulating …
standard of care for patients with advanced hepatocellular carcinoma (HCC). Cumulating …